The market expects GSK (GSK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is ...

Comparatively, GSK underperformed the UK market's 3% decline and the UK Pharmaceuticals industry's 4.8% dip over the last year, highlighting industry-wide pressures.

For new and old investors, taking full advantage of the stock market and investing ... likelihood its share price will decline as well. Thus, the more stocks you own with a #1 or #2 Rank and Scores of ...

GSK has underperformed the broader markets and most of its big pharma peers over the last 10 years. With a tighter focus on branded pharma products, GSK arguably deserves another look by investors ...

GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Why GSK (GSK) is a Top ...

The bottom line is GSK scans as an intriguing buy for both value and income investors right now. That being said, its shares aren't going to yield market-crushing returns anytime soon.

The market expects GSK (GSK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is ...

GSK is a Zacks Rank #3 (Hold) stock, with a Value Style Score of A and VGM Score of A. Shares are currently trading at a forward P/E of 8.6X for the current fiscal year compared to the Medical - ...